All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 6 read as filed from the record and 3 are SI estimates, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2026-08-19.
From the record
Mereo BioPharma Group plc's filings since 2017 show 2 warning events: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2026-08-19) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
4 filed years; profitable in 0 of 4.
From the record
Mereo BioPharma Group plc's 4 filed years say what it did: it rose in 0 of 1 years; the deepest fall was 100% from fiscal 2023 to fiscal 2024; net income was positive in 0 of 4 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Mereo BioPharma Group plc's shareholder treatment is put at 6.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 35% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -102%: lost 102¢ per shareholder dollar. Leverage 11%: owes 11¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Mereo BioPharma Group plc lost about 102 cents for every dollar of shareholders' money. Leverage: it owed about 11 cents per dollar of assets, and net share issuance: its share count grew 7.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 14% of 315 in its family; net margin -8375.6%.
From the record
Mereo BioPharma Group plc's standing among 315 graded names in its industry family: revenue of $500 thousand in fiscal 2025 ranks in the bottom 16% by size; a net margin of -8375.6% ranks in the bottom 11% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
SI estimate 9.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Mereo BioPharma Group plc's leadership is put at 9.6 of 10 with a confidence of 35 of 100, because read from one part only, officer and director changes on Form 8-K over three years, against the people in charge, which ranks in the top 4% of 415 in its family; the record of its people begins on 2024-01-02 (a listing, a merger or a first filing under the rules) and its chief executive and most of the people in charge have filed since then, so the record shows a floor of 2.9 years and cannot see past it; a floor under five years is not read as years in charge. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they set up to do next?
How much room does it have to grow?
top 37% of 273 in its family for room to expand.
From the record
Mereo BioPharma Group plc's room to grow, from the newest filed statements (fiscal 2025): cash of $41 million against no long-term debt tagged leaves 89.3% of its assets as net cash, top 11% of its family; cash from operations less capital spending is -6198.2% of revenue (bottom 10%); research spending of 3553.2% of revenue (top 11%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 48% of 306 in its family for growth drivers.
From the record
Mereo BioPharma Group plc's growth drivers, from the filed years to fiscal 2025: research spending grew -15.5% a year (bottom 22%); capital spending grew 15.4% a year (top 27%) (its annual reports). Mereo BioPharma Group plc tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
SI estimate 3.7/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Mereo BioPharma Group plc's expectations vs reality is put at 3.7 of 10 with a confidence of 35 of 100, because read from one part only, net income against the prior three years' average, which ranks in the bottom 37% of 284 in its family; the record does not carry four filed years of revenue and two of the three parts: revenue against the prior pace, earnings against the prior average, the margin change. A filing that carries the missing parts replaces this estimate with the filed reading.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made